Filtered By:
Therapy: Neoadjuvant Therapy

This page shows you your search results in order of relevance. This is page number 11.

Order by Relevance | Date

Total 36353 results found since Jan 2013.

Ewing's sarcoma/peripheral primitive neuroectodermal tumors of the uterus confirmed with fluorescence in situ hybridization in a 29‐year‐old Chinese female: A case report and published work review
Abstract Ewing's sarcoma/peripheral primitive neuroectodermal tumors (ES/pPNET) are a group of small round cell sarcomas that show varying degrees of neuroectodermal differentiation characterized by translocation involving the EWS gene. Uterine ES/pPNET is a rare entity. A 29‐year‐old Chinese female who presented with abdominal swelling and pain was diagnosed with a primary uterine ES/pPNET on the basis of clinicopathologic, immunohistochemical and fluorescence in situ hybridization (FISH) data. She was given a multimodal treatment, including neoadjuvant, 95% cytoreductive, chemotherapy and radiotherapy. The patient is...
Source: Journal of Obstetrics and Gynaecology Research - October 10, 2014 Category: OBGYN Authors: Tianjin Yi, Ping Wang, Lin Lin, Wei Jiang Tags: Case Report Source Type: research

Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer
Neoadjuvant chemoradiation is an alternative to the surgery-first approach for resectable pancreatic cancer (PDA) and represents the standard of care for borderline resectable (BLR).
Source: Radiotherapy and Oncology - October 15, 2014 Category: Radiology Authors: Jordan Kharofa, Susan Tsai, Tracy Kelly, Clint Wood, Ben George, Paul Ritch, Lauren Wiebe, Kathleen Christians, Douglas B. Evans, Beth Erickson Tags: Original article Source Type: research

Morbidity and Mortality after Major Pulmonary Resections in Patients with Locally Advanced Stage IIIA Non-small Cell Lung Carcinoma who Underwent Induction Therapy
The optimal treatment for patients with locally advanced stage IIIA non-small cell lung carcinoma (NSCLC) remains controversial, but induction therapy is increasingly used. The aim of this study was to evaluate mortality, morbidity, hospital stay and frequency of postoperative complications in stage IIIA NSCLC patients that underwent major pulmonary resections after neoadjuvant chemotherapy or chemoradiation.
Source: Heart, Lung and Circulation - July 30, 2014 Category: Cardiology Authors: Michael Peer, David Stav, Arnold Cyjon, Judith Sandbank, Margarita Vasserman, Zoya Haitov, Lior Sasson, Letizia Schreiber, Tiberiu Ezri, Israel E. Priel, Henri Hayat Tags: Original Article Source Type: research

Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor
Efforts to improve the clinical outcome for patients with localized high-risk prostate cancer have led to the development of neoadjuvant systemic therapies. We review the different modalities of neoadjuvant therapies for localized prostate cancer and highlight emerging treatment approaches including immunotherapy and targeted therapy.
Source: Urologic Oncology: Seminars and Original Investigations - February 4, 2014 Category: Urology & Nephrology Authors: David Y. Lou, Lawrence Fong Tags: Seminar article Source Type: research

The role of diffusion-weighted MRI and F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: A systematic review
After neoadjuvant radiochemotherapy (RCT) for locally advanced rectal cancer, 15–27% of the patients experience a pathological complete response (pCR). This observation raises the question as to whether invasive surgery could be avoided in a selected cohort of patients who obtain a clinical complete response after preoperative RCT. In this respect, there has been growing interest in functional imaging techniques to improve clinical response assessment. This systematic review focuses on the role of diffusion-weighted imaging (DWI) and 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT)...
Source: Radiotherapy and Oncology - November 1, 2014 Category: Radiology Authors: Ines Joye, Christophe M. Deroose, Vincent Vandecaveye, Karin Haustermans Tags: Systematic Review Source Type: research

Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma
Abstract Surgery and chemotherapy are the standard of care for epithelial ovarian cancer, and it is well established that survival outcomes are improved when the surgery results in no or optimal (less than 1 cm) residual disease. However, for patients with bulky disease that may require extensive or radical procedures to accomplish this goal, the use of neoadjuvant chemotherapy followed by interval debulking surgery to simplify the surgery and minimize morbidity has been suggested. Arguably, this is only ideal if this process produces survival outcomes equivalent to those of primary debulking surgery. The purpose...
Source: Cancer and Metastasis Reviews - January 18, 2015 Category: Cancer & Oncology Source Type: research

2070180 Relation Between Effect of Neoadjuvant Chemotherapy in Breast Cancer Patients and Changes of Time to Peak Using Contrast-Enhanced Ultrasound
Second-generation ultrasound contrast agents have enabled real-time, detailed ultrasound (US) imaging of blood flow, and Sonazoid is one of these agents. Sonazoid-enhanced ultrasound (CEUS) of the breast has been shown to have higher diagnostic accuracy of malignancy than contrast-enhanced MRI (MRI). There have been efforts to qualitatively evaluate CEUS using time-intensity curves (TIC). The setting of region of interest (ROI) is important in the evaluation of CEUS using TIC. However, the time changes are constant and independent of ROI setting or CEUS conditions.
Source: Ultrasound in Medicine and Biology - February 17, 2015 Category: Radiology Authors: Shinsaku Kanazawa, Yukio Mitsuzuka, Fumi Saito, Tadatoshi Osaku, Yorichika Kubota, Toshihide Ito, Shunsuke Magoshi, Akemi Kataoka, Hideaki Ogata Source Type: research

Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes
To evaluate gemcitabine-cisplatin (GC) neoadjuvant cisplatin-based chemotherapy (NAC) for pathologic response (pR) and cancer-specific outcomes following radical cystectomy (RC) for muscle-invasive bladder cancer and identify clinical parameters associated with pR.
Source: Urologic Oncology: Seminars and Original Investigations - March 24, 2015 Category: Urology & Nephrology Authors: Nilay M. Gandhi, Alexander Baras, Enrico Munari, Sheila Faraj, Leonardo O. Reis, Jen-Jane Liu, Max Kates, Mohammad Hoque, David Berman, Noah M. Hahn, Mario Eisenberger, George J. Netto, Mark P. Schoenberg, Trinity J. Bivalacqua Tags: Original article Source Type: research

Tumor recurrence and in-field control after multimodality treatment of locally advanced esophageal cancer
Neoadjuvant chemoradiotherapy is used prior to surgery in curative treatment of esophageal cancer (EC). We evaluated the in-field control of this multimodal treatment by extraction of radiation dose parameters and determination of the spatial relation between tumor recurrence location(s) and radiation target volume (RTV).
Source: Radiotherapy and Oncology - March 26, 2015 Category: Radiology Authors: Hendrik Thoen, Wim Ceelen, Tom Boterberg, Elke Van Daele, Piet Pattyn Tags: Original article Source Type: research

Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to nCRT and guide surgical intervention in rectal cancer
Neoadjuvant chemoradiation (nCRT) may lead to complete tumor regression in rectal cancer patients. Prediction of complete response to nCRT may allow a personalized management of rectal cancer and spare patients from unnecessary radical total mesorectal excision with or without sphincter preservation. To identify a gene expression signature capable of predicting complete pathological response (pCR) to nCRT, we carried out a gene expression analysis in 25 pre-treatment biopsies from patients submitted to 5FU-based nCRT using RNA-Seq.
Source: Cancer Genetics and Cytogenetics - March 26, 2015 Category: Genetics & Stem Cells Authors: Camila Lopes-Ramos, Fernanda C. Koyama, Angelita Habr-Gama, Anna Christina M. Salim, Fabiana Bettoni, Paula F. Asprino, Gustavo S. França, Joaquim Gama-Rodrigues, Raphael B. Parmigiani, Rodrigo O. Perez, Pedro A.F. Galante, Anamaria A. Camargo Tags: Original Article Source Type: research

Mp64-10 perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy is associated with increased morbidity and length of stay but not adverse oncologic outcomes
Perioperative blood transfusion (PBT) has been associated with adverse oncologic outcomes, including cancer recurrence, death, and perioperative morbidity for certain malignancies, possibly via an immunologic mechanism. However, reports on the effects of PBT on bladder cancer survival are controversial. As chemotherapy is also immunosuppressive, we analyzed the effect of PBT on morbidity, cancer specific survival (CSS), and overall survival (OS) in a cohort of patients treated with neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for bladder cancer.
Source: The Journal of Urology - April 1, 2015 Category: Urology & Nephrology Authors: Heather Chalfin, Jen-Jane Liu, Nilay Gandhi, Zhaoyong Feng, Bruce Trock, Steven Frank, Trinity Bivalacqua Tags: Bladder Cancer: Natural History and Pathophysiology Source Type: research

Prognostic risk factors for small cell carcinoma of the cervix and impact of platinum-based neoadjuvant chemotherapy
To evaluate prognostic risk factors and the effects of platinum-based neoadjuvant chemotherapy (NACT) among patients with small cell carcinoma of the cervix (SCCC).
Source: International Journal of Gynaecology and Obstetrics - April 10, 2015 Category: OBGYN Authors: Xiong Li, Ru Yang, Yao Jia, Jin Zhou, Ding Ma, Shuang Li Tags: Clinical article Source Type: research

Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial
During the ACCORD 12 randomized trial, an evaluation of the clinical tumor response was prospectively performed after neoadjuvant chemoradiotherapy. The correlations between clinical complete response and patient characteristics and treatment outcomes are reported.
Source: Radiotherapy and Oncology - April 24, 2015 Category: Radiology Authors: Jean-Pierre Gérard, Emmanuel Chamorey, Sophie Gourgou-Bourgade, Karène Benezery, Guy de Laroche, Marc-André Mahé, Valérie Boige, Béata Juzyna Tags: Original article Source Type: research

Soft Tissue Sarcoma with Tongue Metastasis: A Case Report and Literature Review
We report a case of a 41 year old male who was diagnosed with myxofibrosarcoma of the lower extremity and underwent neoadjuvant chemoradiation followed by surgical resection.
Source: Journal of Oral and Maxillofacial Surgery - May 7, 2015 Category: ENT & OMF Authors: Ahmed Dehal, Lian Quach, Erin Garrett, Karim Jreije, Farabi Hussain Tags: Case Report Source Type: research

Three-hole minimally invasive esophagectomy - a safe procedure following neoadjuvant chemotherapy and radiation
Induction therapy followed by esophagectomy has become standard for treatment of intermediate stage esophageal cancer in many centers. Herein we evaluate the feasibility and safety of the three-hole minimally invasive esophagectomy (3HMIE) approach in patients who received induction radiation and chemotherapy.
Source: Seminars in Thoracic and Cardiovascular Surgery - June 19, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Rona Spector, Yifan Zheng, Beow Y. Yeap, Jon O. Wee, Abraham Lebenthal, Scott J. Swanson, David E. Marchosky, Peter C. Enzinger, Harvey J. Mamon, Antoon Lerut, Robert Odze, Amitabh Srivastava, Agoston T. Agoston, Mingkhwan Tippayawang, Raphael Bueno Source Type: research